DM1-SMe

• Description:

  DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin[1].

• UNSPSC:

  12352203

• Hazard Statement:

  H303, H312, H315, H317, H319, H335, H336, H351, H361, H372, H412

• Target:

  ADC Payload; Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dm1-sme.html

• Purity:

  99.08

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(CCSSC)=O)=O)=O)C)=C(C(OC)=C4)Cl)\C)OC)(NC(O3)=O)O)C)([H])O1

• Molecular Formula:

  C36H50ClN3O10S2

• Molecular Weight:

  784.38

• Precautions:

  H303, H312, H315, H317, H319, H335, H336, H351, H361, H372, H412

• References & Citations:

  [1]Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60 (11) :1860-1867. |[2]Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41 (1) :98-107.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  ADC Related

• Clinical Information:

  No Development Reported

• Isoform:

  Maytansinoids

• CAS Number:

  138148-68-2